Y-mAbs Therapeutics YMAB 深 滬
已收盤 08-01 16:00:00 美东时间
4.53
+0.060
+1.34%
華盛通- 最 高4.585
- 今 開4.40
- 成交量 13.88万股
- 最 低 4.2908
- 昨 收 4.47
- 總市值 2.05亿
- 52周最高 16.11
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 3.55
- 委 比 58.68%
- 總股本 4529.58万
- 歷史最高 55.215
- 量 比 0.71
- 振 幅 6.58%
- 歷史最低 2.70
- 每 手 1
- 風險率 4.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Y-Mabs Therapeutics Elects New Director at Annual Meeting
Y-Mabs Therapeutics ( ($YMAB) ) has issued an announcement. On July 11, 2025, Y...
07-16 04:52
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $15
Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and lowers the price target from $20 to $15.
05-30 00:37
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
Y-Mabs Therapeutics ( ($YMAB) ) just unveiled an update. On May 28, 2025, Y-mAb...
05-28 19:29
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Y-mAbs highlighted positive results from Part A of its GD2-SADA Phase 1 trial, demonstrating safety, tolerability, and effective in vivo conjugation of ¹⁷⁷Lu-DOTA. The study showed tumor uptake and absorption at 30 mCi, with no serious adverse events. The company plans to initiate Part 2A (Bridge study) with Proteus, an optimized radiohapten, in H1 2026, followed by Part B in H1 2027. Y-mAbs also expanded its radiopharmaceutical pipeline, targeti...
05-28 10:35
Reported Monday, Y-mAbs Highlights Ongoing Phase 1 Trial Of GD2-SADA PRIT With 177Lu-DOTA At ANR 2025 In Washington, D.C.
The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2+ solid tumors" provides an overview of Trial 1001
05-27 14:24
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Y-mAbs Therapeutics has announced the presentation of GD2-SADA in a clinical trial targeting recurrent or refractory metastatic solid tumors known to express GD2, particularly high-risk neuroblastoma and other GD2+ cancers, with data to be shared soon.
05-26 14:00
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
